Blurbs

J.P. Morgan Remains a Hold on Terns Pharmaceuticals (TERN)

J.P. Morgan analyst Eric Joseph maintained a Hold rating on Terns Pharmaceuticals (TERNResearch Report) on August 9 and set a price target of $5.00. The company’s shares closed yesterday at $2.25.

According to TipRanks, Joseph is a 4-star analyst with an average return of 6.0% and a 55.06% success rate. Joseph covers the Healthcare sector, focusing on stocks such as PTC Therapeutics, Mirati Therapeutics, and Karyopharm Therapeutics.

Terns Pharmaceuticals has an analyst consensus of Hold.

See the top stocks recommended by analysts >>

TERN market cap is currently $56.88M and has a P/E ratio of -1.06.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases.

Read More on TERN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos